U.S. Paper and Forestry Products Stock News

On January 14, 2026, Sana Biotechnology presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting 12‑month survival and function of its hypoimmune-engineered islet cell therapy UP421 in a type 1 diabetes patient without immunosuppression and no therapy-related adverse events. The company also outlined 2026 goals for bringing its stem cell-derived islet therapy SC451 into Phase 1 trials and progressing its in vivo CD19-directed CAR T program SG293, underscoring efforts to...

Avista (AVA) has put a four year general rate case in front of Washington state regulators, a move that could influence how the utility recovers rising costs and funds grid, wildfire, and clean energy investments. See our latest analysis for Avista. Against the backdrop of this multi year rate case, Avista’s share price has been relatively firm, with a 90 day share price return of 4.53% and a 1 year total shareholder return of 13.59%. This suggests steady rather than surging momentum. If this...

AppFolio (APPF) is back on investor radars after the company reshaped its board and appointed experienced finance executive Saori Casey, while also lining up its next earnings release for late January. See our latest analysis for AppFolio. Those board changes and the upcoming January 29 earnings update come as AppFolio’s US$219.67 share price shows mixed momentum, with a 3.16% 1 day share price return but a 30 day share price decline of 4.93%. Its 3 year total shareholder return of 92.81%...

In recent days, analysts have reiterated their broadly positive stance on Monster Beverage, highlighting its leading position in energy drinks and its long-term distribution and manufacturing partnership with Coca-Cola, which also holds a 19.5% ownership stake. What stands out is Monster’s combination of strong free cash flow generation, disciplined cost control, and high returns on capital, which together point to a business that has become less capital intensive while still investing...

Event context and recent price performance With no single headline event driving attention to Oceaneering International (OII) today, investors may be looking at the stock’s recent returns and fundamentals to understand what the current pricing might reflect. See our latest analysis for Oceaneering International. With the share price at US$27.27, Oceaneering International has seen short term momentum, with a 30 day share price return of 13.34% and a 90 day share price return of 18.00%. The 3...

Earlier this month, the World Orphan Drug Alliance and Syndax Pharmaceuticals announced a collaboration to expand global access to Syndax’s first-in-class menin inhibitor, Revuforj (revumenib), via a Managed Access Program for eligible acute leukemia patients outside the U.S. This move meaningfully broadens potential real-world use of Revuforj in hard-to-treat blood cancers, complementing its existing FDA approvals in specific relapsed or refractory KMT2A-translocated and NPM1-mutated...

Earlier this month, the UK Competition and Markets Authority ordered Aramark to unwind its majority acquisition of offshore caterer Entier due to competition concerns, forcing the company to sell the business it had combined with its existing UK operations. This intervention highlights how regulatory scrutiny can reshape Aramark’s expansion efforts, particularly in specialized markets where consolidation risks reducing customer choice. We’ll now examine how being compelled to divest Entier...

If you are wondering whether Okta's current share price lines up with its underlying worth, this article will help you unpack what the market might be pricing in today. Okta's share price closed at US$89.55, with returns of 2.6% over the last year, 7.1% year to date, a 30.3% gain over three years, and a 66.1% decline over five years, so the stock has treated different time frames very differently. Recent headlines around Okta have focused on its role in identity and access management and how...

What HF Sinclair’s Recent Share Moves Signal for Investors HF Sinclair (DINO) has seen mixed share performance recently, with a 2.5% gain over the past month and a 6.2% decline over the past 3 months. This has put fresh attention on its current valuation. See our latest analysis for HF Sinclair. At a share price of US$48.63, HF Sinclair’s short term share price pressure, including a 1 day decline of 2.4% and a 7 day decline of 3.3%, contrasts with its 1 year total shareholder return of 40.6%...

On December 31, 2025, Range Resources Corporation announced it would fully redeem its US$600,000,000 8.25% senior notes due 2029 on January 15, 2026, at 101.375% of par plus accrued interest, funded via its existing revolving credit facility. This move retires high-coupon debt while shifting funding to shorter-term bank borrowing, putting the company’s balance sheet choices under closer investor and analyst scrutiny. Next, we’ll examine how funding this bond redemption through the revolving...

Earlier this week, Edgewise Therapeutics used its presentation at the 44th J.P. Morgan Healthcare Conference to outline 2026 milestones, including pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy, Phase 2 readouts for EDG-7500 in hypertrophic cardiomyopathy, and continued development of its early-stage heart failure candidate EDG-15400. A distinctive aspect of the update is Edgewise’s attempt to build an integrated neuromuscular and cardiovascular franchise, with...

In recent months, World Kinect Corporation received a consensus “Reduce” rating from six analysts, reported a quarterly update with revenue slightly ahead of expectations but earnings per share below consensus and a 10.5% year-on-year revenue decline, and confirmed a quarterly dividend implying an annualized yield of 2.9% payable on January 16. This mix of cautious analyst sentiment, weaker earnings, and an ongoing dividend payout highlights a tension between income appeal and concerns about...

Recent analyst reports on Marex Group (MRX) highlight increased optimism around the company’s earnings outlook. Several firms have revised their forecasts higher and reiterated positive ratings, drawing fresh attention to the stock. See our latest analysis for Marex Group. The recent earnings optimism has coincided with a 32.28% 90 day share price return and a 21.80% total shareholder return over the past year, suggesting momentum has been building around Marex Group, which had a last close...

Earlier this week, Truist Financial Corporation announced it had hired former JPMorgan Chase executive Mark Cuccinello as Head of Structured Credit, overseeing asset-based lending, working capital solutions, and equipment finance within its Wholesale Banking platform. This leadership move, alongside analysts’ more optimistic earnings expectations, highlights Truist’s focus on strengthening fee-rich structured credit capabilities and aligning its lending franchises more tightly with corporate...

In recent weeks, Brinker International’s Chili’s brand extended its multi-year NASCAR sponsorship with Spire Motorsports, while analysts and commentators such as Jim Cramer and Evercore’s David Palmer highlighted the company’s management execution, pricing discipline, and value proposition for middle-income guests. At the same time, Brinker's upcoming January 28, 2026 earnings call and upward earnings estimate revisions have focused attention on how its operational decisions and marketing...

In recent days, eBay released its first climate transition plan, setting a net-zero greenhouse gas emissions goal by 2045 and outlining substantial cuts to operational and supply-chain emissions, including freight and shipping. A distinctive aspect of the plan is eBay’s intent to lean on its recommerce marketplace and circular fashion initiatives to curb logistics emissions while supporting more sustainable consumer behaviour. We’ll now explore how eBay’s new net-zero roadmap, particularly...

Recent comments from Merit Medical Systems (MMSI) leadership put mergers and acquisitions firmly in focus. The company highlighted disciplined deal making, a growing cash war chest, and an intent to target specific gaps in its portfolio. See our latest analysis for Merit Medical Systems. The recent leadership shift, fresh revenue guidance and clear M&A focus come against a mixed backdrop, with a 1 year total shareholder return of 20% decline contrasting with 17.2% and 42.38% total shareholder...

McCormick & Company, Incorporated recently announced a two-year collaboration with Paris Hilton and her media company 11:11 Media, centered on a new advertising campaign that links its spices, seasonings, and extracts with memorable food, film, and TV moments. The partnership is intended to help McCormick evolve its brand for younger consumers while honoring its heritage, positioning the company as a “house of flavor” that stays culturally relevant to the next generation of home cooks. We’ll...

In recent days, several research firms reaffirmed positive ratings on Kirby Corporation and expressed increased confidence in its operational and market positioning. This cluster of upbeat analyst views adds fresh external validation to Kirby’s existing investment case around marine transport capacity and industrial demand exposure. We’ll now examine how this growing analyst confidence could reshape Kirby’s investment narrative and investors’ assessment of its long-term prospects. AI is...

In late 2025, Schneider National reported US$60,000 in Q4 lobbying focused on trucking policy issues and marked the first anniversary of its Cowan Systems acquisition, which has expanded its Dedicated fleet and regional reach while supporting revenue tied to more contracted freight. At the same time, analysts have maintained generally positive views on Schneider National, highlighting the Cowan integration and a shift toward more stable, dedicated and intermodal revenue even as insiders have...

Dyne Therapeutics (DYN) is back in focus after its appearance at the 44th Annual J.P. Morgan Healthcare Conference, where CEO John G. Cox outlined progress in programs targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy. See our latest analysis for Dyne Therapeutics. Despite recent enthusiasm around Dyne’s neuromuscular programs and conference visibility, the 30 day share price return of 11.61% and year to date share price return of 9.70% contrast with a 1 year total...

Array Technologies (ARRY) has been in focus after a sharp business recovery, marked by strong revenue growth, sizeable bookings and the APA acquisition. Together, these developments have shifted how many investors view the stock. See our latest analysis for Array Technologies. Those operational headlines have been reflected in the trading pattern, with a 14.68% 30 day share price return and a 9.83% 90 day gain, even though the year to date share price return is slightly negative and the 3...

Why STAAR Surgical Is Back in Focus After the Failed Alcon Deal STAAR Surgical (STAA) is back on investors’ radar after shareholders rejected its cash sale to Alcon and the company confirmed it will continue as an independent, publicly traded business. That decision has quickly been followed by a broad refresh of the boardroom, new committee structures and an active search for a new chief executive, all with heavy involvement from STAAR’s largest shareholders. See our latest analysis for...

AZZ Inc. recently reported third-quarter fiscal 2026 results showing higher sales of US$425.75 million and net income of US$41.08 million year on year, while also narrowing full-year revenue guidance to US$1.625 billion–US$1.7 billion, authorizing a US$0.20 per share dividend, and completing a share buyback of 1,134,067 shares since 2020. Management highlighted strong momentum in Metal Coatings, an active pipeline of small bolt-on acquisitions, and ongoing capital returns via dividends and...